Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN (P8-3.005)
Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available
10.1212/wnl.0000000000211441